SREBP1 转录激活 NHE3 损害心肌收缩并加重心力衰竭
本研究探讨 SREBP1 在非代谢合并症的射血分数降低的心力衰竭(HFrEF)中对离子调节的作用。研究利用 HFrEF 患者心肌、小鼠主动脉缩窄模型及心肌细胞特异性转基因/敲降模型,发现 SREBP1 直接转录激活 NHE3,导致钙处理紊乱和收缩功能障碍,揭示 SREBP1 在心力衰竭中的新机制及潜在治疗靶点。
要点
- SREBP1 在 HFrEF 心肌中被激活,直接转录上调 NHE3(SLC9A3)。
- 心肌细胞 SREBP1 过表达损害钙处理和收缩力,不伴脂质蓄积;敲降 NHE3 可恢复功能。
- 靶向 SREBP1-NHE3 轴可能为 HFrEF 提供新治疗策略。
核心结论
- SREBP1 通过直接转录激活心肌 NHE3,导致钠钙超载和收缩功能受损,构成心力衰竭进展中的新非经典机制,并可作为治疗靶点。
研究设计与样本
- 分析 HFrEF 患者(扩张型心肌病、无糖尿病或高脂血症)和 TAC 小鼠心肌组织。
- 生成心肌细胞特异性 SREBP1 转基因(Srebp1a-Tg)和敲降(Cre-Srebf1f/f)小鼠,并使用 AAV9 载体(cTnT 启动子)表达/敲降 NHE3 或 SREBP1 以进行功能验证。
主要发现
- SREBP1 在人类 HFrEF 心脏和 TAC 小鼠心脏中被激活。
- Srebp1a-Tg 小鼠心肌收缩力下降,钙处理异常,无脂质蓄积。
- 转录组学显示 NHE3 表达升高,ChIP-seq、ChIP 和启动子报告实验证实 SREBP1 直接调控 SLC9A3 转录。
- 心肌细胞 Srebf1 敲降(TAC 小鼠)降低 NHE3 活性,敲降 Srebf1 或 Slc9a3 改善钙处理和心功能。
- NHE3 过表达导致收缩损害,抵消 SREBP1 敲降的保护效应。
关键数值与推荐
- SREBP1 激活在 HFrEF 患者心脏(扩张型心肌病)和 TAC 小鼠心肌中均被观察到(原文未报告具体定量数值)。
- Srebp1a-Tg 小鼠中 NHE3 活性增强,TAC 小鼠中 Srebf1 敲降降低 NHE3 活性(原文未报告测得的活性数值)。
- 敲降 NHE3 缓解钠和钙超载并恢复收缩功能(原文未报告具体功能参数数值)。
局限性
- 原文未报告具体样本量、统计阈值和效应量数值。
- 研究基于小鼠模型和离体心肌细胞,临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is characterized by impaired contractility and high mortality. Dysregulation of intracellular ion (ie, Na+/H+ and Ca2+) cycling underlies reduced cardiac contractility. The mechanisms linking myocardial stress to this ion dysregulation remain incompletely understood. Although the metabolic transcription factor SREBP1 (sterol regulatory element-binding protein 1) remodels cardiac metabolism, its role in HFrEF without metabolic comorbidities, particularly regarding ion handling, remains undefined. METHODS: Cardiac tissues from HFrEF patients and mice subjected to transverse aortic constriction (TAC) were analyzed for SREBP1 transactivation of sodium-hydrogen exchanger 3 (NHE3). Cardiomyocyte-specific SREBP1 transgenic (Srebp1a-Tg) and knockdown (Cre-Srebf1f/f) mice were generated. AAV9 vectors carrying Slc9a3 (encoding NHE3), Srebp1a or shRNA against Slc9a3, driven by the cardiomyocyte-specific cTnT promoter, were used to validate the role of the SREBP1-NHE3 in HFrEF. RESULTS: SREBP1 was activated in human hearts with HFrEF because of dilated cardiomyopathy, but without diabetes or hyperlipidemia, and in TAC-induced HFrEF mouse hearts. Srebp1a-Tg mice exhibited impaired cardiac contractility with dysregulated calcium handling in cardiomyocytes without apparent lipid accumulation. Transcriptomics analysis identified increased NHE3 expression in Srebp1a-Tg mice, confirmed by NHE3 upregulation in TAC hearts and human failing hearts. ChIP-seq, ChIP, and promoter reporter assay demonstrated direct transcriptional regulation of SLC9A3 (encoding NHE3) by SREBP1. NHE3 activity was enhanced in cardiomyocytes isolated from Srebp1a-Tg mice or those underwent TAC, whereas cardiomyocyte-specific Srebf1 knockdown in TAC mice reduced NHE3 activity. Cardiomyocyte-specific knockdown of Srebf1 or Slc9a3 restored calcium handling and improved cardiac function in TAC mice. In Srebp1a-Tg mice, NHE3 knockdown alleviated Na+ and Ca2+ overload and rescued cardiac systolic dysfunction. Conversely, NHE3 overexpression caused contractile impairment in both Cre-Srebf1f/f mice and controls, which offset the protective effect because of SREBP1 loss in the context of Na+ and Ca2+ overload. CONCLUSIONS: SREBP1 directly transactivates cardiac NHE3 during the progression of HFrEF, leading to dysregulated calcium handling and impaired contractility, revealing a novel, noncanonical role for SREBP1 in the pathophysiology of heart failure and offering a potential new therapeutic target.
引用
- Gu, Wen, Liu, et al. SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure. Circulation. 2026. PMID: 42170742. doi:10.1161/CIRCULATIONAHA.126.079823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。